AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Consensus Recommendation of “Moderate Buy” from Analysts

AgomAb Therapeutics NV (NASDAQ:AGMB) has been given an average recommendation of “Moderate Buy” by the eight analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $37.50.

AGMB has been the topic of a number of recent analyst reports. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating on the stock. HC Wainwright initiated coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They set a “buy” rating and a $35.00 target price for the company. B. Riley Financial began coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. Piper Sandler started coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. Finally, Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th.

AgomAb Therapeutics Stock Up 6.4%

Shares of AGMB stock opened at $15.78 on Friday. The firm’s 50-day moving average is $13.35 and its two-hundred day moving average is $12.51. AgomAb Therapeutics has a 12 month low of $8.75 and a 12 month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, equities analysts predict that AgomAb Therapeutics will post -1.76 EPS for the current fiscal year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.